Combined treatment with oral metronidazole and N-acetylcysteine is effective in ethylmalonic encephalopathy

Nat Med. 2010 Aug;16(8):869-71. doi: 10.1038/nm.2188. Epub 2010 Jul 25.

Abstract

Ethylmalonic encephalopathy is caused by mutations in ETHE1, a mitochondrial matrix sulfur dioxygenase, leading to failure to detoxify sulfide, a product of intestinal anaerobes and, in trace amounts, tissues. Metronidazole, a bactericide, or N-acetylcysteine, a precursor of sulfide-buffering glutathione, substantially prolonged the lifespan of Ethe1-deficient mice, with the combined treatment being additive. The same dual treatment caused marked clinical improvement in five affected children, with hardly any adverse or side effects.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetylcysteine / administration & dosage*
  • Acetylcysteine / adverse effects
  • Administration, Oral
  • Animals
  • Anti-Infective Agents / administration & dosage
  • Anti-Infective Agents / adverse effects
  • Brain Diseases, Metabolic, Inborn / drug therapy*
  • Brain Diseases, Metabolic, Inborn / genetics
  • Brain Diseases, Metabolic, Inborn / metabolism
  • Brain Diseases, Metabolic, Inborn / mortality
  • Child, Preschool
  • Dioxygenases / genetics
  • Drug Combinations
  • Drug Evaluation, Preclinical
  • Female
  • Humans
  • Infant
  • Male
  • Malonates / metabolism
  • Metronidazole / administration & dosage*
  • Metronidazole / adverse effects
  • Mice
  • Mice, Knockout
  • Mitochondrial Proteins / genetics
  • Treatment Outcome

Substances

  • Anti-Infective Agents
  • Drug Combinations
  • Malonates
  • Mitochondrial Proteins
  • Metronidazole
  • ethylmalonic acid
  • Dioxygenases
  • ETHE1 protein, mouse
  • Acetylcysteine